What Is Graft-versus-Host Disease (GVHD)? (2026 Update)

Graft-versus-host disease is a reaction in allogeneic hematopoietic stem cell transplantation in which the donor's immune cells attack the patient's skin, gut, liver, and other organs. It is controlled with immunosuppressants, and early detection is essential.

Key Takeaways

• Graft-versus-host disease (GVHD) is a reaction in allogeneic hematopoietic stem cell transplantation in which the donor's immune cells attack the patient's skin, gut, liver, and other organs (National Cancer Center Korea, NCCN patient guidelines).
• GVHD does not occur with autologous transplants (using the patient's own cells) — it can only arise in allogeneic transplants, which use a donor's cells.
• To prevent this, immunosuppressants are used after transplantation, and for allogeneic transplants it's common practice to monitor patients closely, staying near the treating institution for roughly 100 days post-transplant, to manage GVHD and infection risk.
• Symptoms include skin rash, diarrhea, elevated liver enzymes, and dryness of the eyes and mouth. It can appear acutely early on, or develop months later as a chronic form.
• Severity ranges widely from mild to severe, making early detection and control critical.

Why Does Graft-versus-Host Disease Occur?

• In allogeneic transplantation, the donor's immune cells enter the patient's body along with the donor's hematopoietic stem cells. GVHD occurs when these immune cells recognize the patient's body as 'foreign' and attack it.
• Autologous transplants return previously collected cells from the patient's own body, so this kind of rejection reaction doesn't happen. Allogeneic transplants, on the other hand, benefit from the donor's immune cells attacking any remaining cancer cells — but that same immunity can also attack the patient's skin, gut, and liver, making management considerably more complex.

What Symptoms Appear?

• Symptoms appear as skin rash, diarrhea, elevated liver enzymes, and dryness of the eyes and mouth. It can occur acutely in the early period after transplant, or develop into a chronic form months later.
• Because this condition ranges widely from mild to severe, patients are advised to check daily for changes such as skin rash, diarrhea, and dryness of the eyes and mouth, and to notify the treating medical team immediately. Early detection and control are key.

How Is It Managed and Prevented?

• In allogeneic transplantation, immunosuppressants are used after the procedure to prevent GVHD. While on immunosuppressants, patients are regularly checked for reactivation of viral infections.
• Engraftment — the process by which the new cells settle in and begin producing blood — typically takes 2 to 4 weeks, during which patients are highly vulnerable to infection and stay in a sterile room. Even after engraftment, it's common practice to have frequent outpatient visits while staying near the hospital for roughly 100 days post-transplant, to manage GVHD and infection risk.
• Recovery tends to be slow, with physical strength and immune function taking months to return, and many patients need to restart their vaccinations from scratch.

FAQ — Is Graft-versus-Host Disease Really That Dangerous?

Severity ranges widely from mild to severe. Symptoms can appear in the skin, gut, liver, eyes, and mouth, and early detection with immunosuppressant control is important. For this reason, patients are advised to check for symptom changes daily after transplant and report them immediately.

FAQ — When Can Patients Return Home?

For allogeneic transplants, the standard for returning home is often around 100 days post-transplant, to manage GVHD and infection risk; for autologous transplants, it's often 2 to 3 weeks after hospital discharge. This can be adjusted based on engraftment status, immunosuppressant dosage, and the tests and medications available locally, with the final decision made by the treating medical team.

Sources and Notes

• This article was written based on notes on hematopoietic stem cell transplantation and blood cancer (National Cancer Center Korea, NCCN patient guidelines).
• This content is intended to provide general medical information. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. For an accurate diagnosis and treatment plan, please be sure to consult with your medical team.